Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease

Severe Liver Disease Group, the Professional Committee for Hepatology, Chinese Research Hospital Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association

doi:10.3969/j.issn.1001-5256.2022.02.011

Volume 38 Issue 2

Feb. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(2): 311-317

PDF( 2799 KB)

Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease

DOI: 10.3969/j.issn.1001-5256.2022.02.011

Severe Liver Disease Group, the Professional Committee for Hepatology, Chinese Research Hospital Association,
Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association

Received Date: 2022-02-14
Accepted Date: 2022-02-16
Published Date: 2022-02-20

Abstract

Abstract

The prognosis of severe liver disease combined with invasive fungal infection (IFI) is poor, and the clinical manifestations are often atypical. Moreover, most of the antifungal drugs are metabolized in the liver, with severe toxicities and side effects, making clinical diagnosis and treatment difficult. The Professional Committee for Hepatology, the Chinese Research Hospital Association and the Hepatology Branch of China Medical Association organized relevant experts to formulate an expert consensus based on the characteristics of patients with severe liver disease combined with IFI, in order to provide reference for medical personnel in making decisions on the diagnosis and treatment.
- Liver Diseases,
- Invasive Fungal Infections,
- Consensus

HU Jinhua, 13910020608@163.com; HAN Tao, hantaomd@126.com

FullText(HTML)

References(81)

References

[1]	FERRARESE A, CATTELAN A, CILLO U, et al. Invasive fungal infection before and after liver transplantation[J]. World J Gastroenterol, 2020, 26(47): 7485-7496. DOI: 10.3748/wjg.v26.i47.7485.
[2]	SCHMIEDEL Y, ZIMMERLI S. Common invasive fungal diseases: An overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia[J]. Swiss Med Wkly, 2016, 146: w14281. DOI: 10.4414/smw.2016.14281.
[3]	BAJAJ JS, REDDY RK, TANDON P, et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort[J]. Am J Gastroenterol, 2018, 113(4): 556-563. DOI: 10.1038/ajg.2017.471.
[4]	VERMA N, SINGH S, TANEJA S, et al. Invasive fungal infections amongst patients with acute-on-chronic liver failure at high risk for fungal infections[J]. Liver Int, 2019, 39(3): 503-513. DOI: 10.1111/liv.13981.
[5]	WANG Y, XU X, TONG JJ, et al. Etiological characteristics and influencing factors for concurrent fungal infection in liver failure patients[J]. Chin J Nosocomiol, 2020, 30(14): 2105-2109. DOI: 10.11816/cn.ni.2020-192694. 王宇, 许祥, 童晶晶, 等. 肝衰竭患者并发真菌感染病原学及影响因素[J]. 中华医院感染学杂志, 2020, 30(14): 2105-2109. DOI: 10.11816/cn.ni.2020-192694.
[6]	FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: Prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880. DOI: 10.1136/gutjnl-2017-314240.
[7]	PIANO S, SINGH V, CARACENI P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380. e10. DOI: 10.1053/j.gastro.2018.12.005.
[8]	BARTOLETTI M, GIANNELLA M, LEWIS R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients[J]. Clin Microbiol Infect, 2018, 24(5): 546. DOI: 10.1016/j.cmi.2017.08.001.
[9]	FIORE M, LEONE S. Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective[J]. World J Gastroenterol, 2016, 22(34): 7742-7747. DOI: 10.3748/wjg.v22.i34.7742.
[10]	GONG M, LI J. Misdiagnosis of hepatitis B cirrhosis with Cryptococcus neoformans meningitis: An analysis of 18 cases[J]. Clin Focus, 2010, 25(1): 62-63. 宫嫚, 李筠. 乙型肝炎肝硬化合并新型隐球菌性脑膜炎18例误诊分析[J]. 临床荟萃, 2010, 25(1): 62-63.
[11]	GAO N, XU CF, CHEN WC. A case of liver cirrhosis with Cryptococcus neoformans meningitis[J]. Chin J Dig, 2006, 26(11): 787. DOI: 10.3760/j.issn:0254-1432.2006.11.031. 高楠, 许春舫, 陈卫昌. 肝硬化合并新型隐球菌脑膜炎一例[J]. 中华消化杂志, 2006, 26(11): 787. DOI: 10.3760/j.issn:0254-1432.2006.11.031.
[12]	SU HB, WANG HF, LI C, et al. Liver failure complicated by multi-system invasive fungal infections[J]. Infect Dis Info, 2010, 23(2): 95-97. DOI: 10.3969/j.issn.1007-8134.2010.02.010. 苏海滨, 王慧芬, 李晨, 等. 肝衰竭并发多系统侵袭性真菌感染临床分析[J]. 传染病信息, 2010, 23(2): 95-97. DOI: 10.3969/j.issn.1007-8134.2010.02.010.
[13]	LIU JJ, JIAO QH. Drug resistance of liver failure with fungal infection: An analysis of 96 cases[J]. Chin Hepatol, 2013, 18(11): 793-794. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201311024.htm 刘俊杰, 焦秋红. 96例肝衰竭合并真菌感染耐药性分析[J]. 肝脏, 2013, 18(11): 793-794. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201311024.htm
[14]	BASSETTI M, PEGHIN M, CARNELUTTI A, et al. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: A multicenter study[J]. Intensive Care Med, 2017, 43(4): 509-518. DOI: 10.1007/s00134-017-4717-0.
[15]	TARIQ T, IRFAN FB, FARISHTA M, et al. Spontaneous fungal peritonitis: Micro-organisms, management and mortality in liver cirrhosis-A systematic review[J]. World J Hepatol, 2019, 11(7): 596-606. DOI: 10.4254/wjh.v11.i7.596.
[16]	LAHMER T, BRANDL A, RASCH S, et al. Prevalence and outcome of invasive pulmonary aspergillosis in critically ill patients with liver cirrhosis: An observational study[J]. Sci Rep, 2019, 9(1): 11919. DOI: 10.1038/s41598-019-48183-4.
[17]	SU HB, WANG HF, YAN T, et al. The clinical characteristics of hepatic failure with aspergillosis[J]. Chin J Hepatol, 2010, 18(7): 520-522. DOI: 10.3760/cma.j.issn.1007-3418.2010.07.012. 苏海滨, 王慧芬, 闫涛, 等. 肝衰竭合并曲霉菌感染的临床特征分析[J]. 中华肝脏病杂志, 2010, 18(7): 520-522. DOI: 10.3760/cma.j.issn.1007-3418.2010.07.012.
[18]	HADFIELD NJ, SELVENDRAN S, JOHNSTON MP. Fatal Pneumocystis jirovecii pneumonia in a non-immunocompromised patient with alcohol-related liver cirrhosis[J]. Scott Med J, 2019, 64(4): 148-153. DOI: 10.1177/0036933019872629.
[19]	MATSUBARA VH, BANDARA HM, MAYER MP, et al. Probiotics as antifungals in mucosal candidiasis[J]. Clin Infect Dis, 2016, 62(9): 1143-1153. DOI: 10.1093/cid/ciw038.
[20]	LING Z, LIU X, CHENG Y, et al. Blood microbiota as a potential noninvasive diagnostic biomarker for liver fibrosis in severely obese patients: Choose carefully[J]. Hepatology, 2017, 65(5): 1775-1776. DOI: 10.1002/hep.28987.
[21]	OTERO SANCHEZ L, KARAKIKE E, NJIMI H, et al. Clinical course and risk factors for infection in severe forms of alcohol- associated liver disease[J]. Hepatology, 2021, 74(5): 2714-2724. DOI: 10.1002/hep.31984.
[22]	BARTOLETTI M, RINALDI M, PASQUINI Z, et al. Risk factors for candidaemia in hospitalized patients with liver cirrhosis: A multicentre case-control-control study[J]. Clin Microbiol Infect, 2021, 27(2): 276-282. DOI: 10.1016/j.cmi.2020.04.030.
[23]	BASSETTI M, GARNACHO-MONTERO J, CALANDRA T, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients[J]. Intensive Care Med, 2017, 43(9): 1225-1238. DOI: 10.1007/s00134-017-4731-2.
[24]	GUSTOT T, FERNANDEZ J, SZABO G, et al. Sepsis in alcohol- related liver disease[J]. J Hepatol, 2017, 67(5): 1031-1050. DOI: 10.1016/j.jhep.2017.06.013.
[25]	WANG CP, SHAO HL, WANG P, et al. The spectrum of pathogens in 187 cases of pulmonary fungal disease diagnosed by histopathology-a retrospective analysis[J]. Chin J Tuberc Respir Dis, 2021, 44(1): 28-31. DOI: 10.3760/cma.j.cn112147-20200314-00332. 王翠萍, 邵汇琳, 王澎, 等. 组织病理学诊断的肺真菌病187例菌种分布的回顾性分析[J]. 中华结核和呼吸杂志, 2021, 44(1): 28-31. DOI: 10.3760/cma.j.cn112147-20200314-00332.
[26]	LI Z, LI Y, CHEN Y, et al. Trends of pulmonary fungal infections from 2013 to 2019: An AI-based real-world observational study in Guangzhou, China[J]. Emerg Microbes Infect, 2021, 10(1): 450-460. DOI: 10.1080/22221751.2021.1894902.
[27]	CHEN LY, KUO SC, WU HS, et al. Associated clinical characteristics of patients with candidemia among different Candida species[J]. J Microbiol Immunol Infect, 2013, 46(6): 463-468. DOI: 10.1016/j.jmii.2012.08.001.
[28]	SCHNABEL RM, LINSSEN CF, GUION N, et al. Candida pneumonia in intensive care unit?[J]. Open Forum Infect Dis, 2014, 1(1): ofu026. DOI: 10.1093/ofid/ofu026.
[29]	CHEN J, YANG Q, HUANG J, et al. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: A retrospective-cohort study[J]. Int J Med Sci, 2013, 10(12): 1625-1631. DOI: 10.7150/ijms.6824.
[30]	WANG Y, HU JH. Clinical features of patients with liver failure and fungal infections and influencing factors for prognosis[J]. J Clin Hepatol, 2019, 35(2): 419-423. DOI: 10.3969/j.issn.1001-5256.2019.02.041. 王宇, 胡瑾华. 肝衰竭合并真菌感染发病特点及预后影响因素[J]. 临床肝胆病杂志, 2019, 35(2): 419-423. DOI: 10.3969/j.issn.1001-5256.2019.02.041.
[31]	FAN WH, LUO YP, LIAO W, et al. Predisposing factors and clinical features of liver failure with fungal infection[J]. Chin Hepatol, 2020, 25(4): 438-440. DOI: 10.3969/j.issn.1008-1704.2020.04.035. 范文瀚, 罗怡平, 廖威, 等. 肝衰竭合并真菌感染的易感因素及临床特点[J]. 肝脏, 2020, 25(4): 438-440. DOI: 10.3969/j.issn.1008-1704.2020.04.035.
[32]	ZHANG X, YANG M, HU J, et al. Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: Clinical presentation, risk factors, and outcomes[J]. J Int Med Res, 2018, 46(2): 819-827. DOI: 10.1177/0300060517729907.
[33]	QIAO JC. Misdiagnosis of Pneumocystis carinii disease: A case report[J]. Clin Misdiagn Misther, 2005, 18(4): 240-241. DOI: 10.3969/j.issn.1002-3429.2005.04.009. 乔锦昌. 卡氏肺孢子虫病一例误诊报告[J]. 临床误诊误治, 2005, 18(4): 240-241. DOI: 10.3969/j.issn.1002-3429.2005.04.009.
[34]	HASSAN EA, ABD EL-REHIM AS, HASSANY SM, et al. Fungal infection in patients with end-stage liver disease: Low frequency or low index of suspicion[J]. Int J Infect Dis, 2014, 23: 69-74. DOI: 10.1016/j.ijid.2013.12.014.
[35]	CORNELY OA, ARIKAN-AKDAGLI S, DANNAOUI E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014, 20 Suppl 3: 5-26. DOI: 10.1111/1469-0691.12371.
[36]	WANG G, ZHAO TC, ZHANG XJ, et al. Talaromyces marneffei detected in peripheral blood smear: An analysis of 2 cases[J]. Chin J Clin Lab Sci, 2019, 37(1): 75-76. DOI: 10.13602/j.cnki.jcls.2019.01.20. 王庚, 赵天赐, 张小江, 等. 外周血涂片检出马尔尼菲蓝状菌2例[J]. 临床检验杂志, 2019, 37(1): 75-76. DOI: 10.13602/j.cnki.jcls.2019.01.20.
[37]	DONNELLY JP, CHEN SC, KAUFFMAN CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium[J]. Clin Infect Dis, 2020, 71(6): 1367-1376. DOI: 10.1093/cid/ciz1008.
[38]	LI B, HE Q, RUI Y, et al. Rapid detection for infected ascites in cirrhosis using metagenome next-generation sequencing: A case series[J]. Liver Int, 2022, 42(1): 173-179. DOI: 10.1111/liv.15083.
[39]	CARBONNELLE E, MESQUITA C, BILLE E, et al. MALDI-TOF mass spectrometry tools for bacterial identification in clinical microbiology laboratory[J]. Clin Biochem, 2011, 44(1): 104-109. DOI: 10.1016/j.clinbiochem.2010.06.017.
[40]	GALAR A, YUSTE JR, ESPINOSA M, et al. Clinical and economic impact of rapid reporting of bacterial identification and antimicrobial susceptibility results of the most frequently processed specimen types[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(9): 2445-2452. DOI: 10.1007/s10096-012-1588-8.
[41]	BOCH T, REINWALD M, SPIESS B, et al. Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1-3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study[J]. J Crit Care, 2018, 47: 198-203. DOI: 10.1016/j.jcrc.2018.07.001.
[42]	TERRERO-SALCEDO D, POWERS-FLETCHER MV. Updates in laboratory diagnostics for invasive fungal infections[J]. J Clin Microbiol, 2020, 58(6): e01487-19. DOI: 10.1128/JCM.01487-19.
[43]	ZHOU W, LI H, ZHANG Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis[J]. J Clin Microbiol, 2017, 55(7): 2153-2161. DOI: 10.1128/JCM.00345-17.
[44]	Chinese adult candidiasis diagnosis and management expert consensus group. Chinese consensus on the diagnosis and management of adult candidiasis[J]. Chin J Infect Dis, 2020, 38(1): 29-43. DOI: 10.3760/cma.j.issn.1000-6680.2020.01.005. 中国成人念珠菌病诊断与治疗专家共识组. 中国成人念珠菌病诊断与治疗专家共识[J]. 中华传染病杂志, 2020, 38(1): 29-43. DOI: 10.3760/cma.j.issn.1000-6680.2020.01.005.
[45]	Chinese Society of Infectious Diseases, Chinese Medical Association. Expert consensus on the diagnosis and treatment of cryptococcal meningitis[J]. Chin J Infect Dis, 2018, 36(4): 193-199. DOI: 10.3760/cma.j.issn.1000-6680.2018.04.001. 中华医学会感染病学分会. 隐球菌性脑膜炎诊治专家共识[J]. 中华传染病杂志, 2018, 36(4): 193-199. DOI: 10.3760/cma.j.issn.1000-6680.2018.04.001.
[46]	CORDONNIER C, PAUTAS C, MAURY S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial[J]. Clin Infect Dis, 2009, 48(8): 1042-1051. DOI: 10.1086/597395.
[47]	SHIELDS RK, NGUYEN MH, CLANCY CJ. Clinical perspectives on echinocandin resistance among Candida species[J]. Curr Opin Infect Dis, 2015, 28(6): 514-522. DOI: 10.1097/QCO.0000000000000215.
[48]	MARTIAL LC, BRVGGEMANN RJ, SCHOUTEN JA, et al. Dose reduction of caspofungin in intensive care unit patients with child pugh B will result in suboptimal exposure[J]. Clin Pharmacokinet, 2016, 55(6): 723-733. DOI: 10.1007/s40262-015-0347-2.
[49]	ULLMANN AJ, CORNELY OA, DONNELLY JP, et al. ESCMID^* guideline for the diagnosis and management of Candida diseases 2012: Developing European guidelines in clinical microbiology and infectious diseases[J]. Clin Microbiol Infect, 2012, 18 Suppl 7: 1-8. DOI: 10.1111/1469-0691.12037.
[50]	DESAI A, SCHMITT-HOFFMANN AH, MUJAIS S, et al. Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment[J]. Antimicrob Agents Chemother, 2016, 60(5): 3025-3031. DOI: 10.1128/AAC.02942-15.
[51]	CHATELON J, CORTEGIANI A, HAMMAD E, et al. Choosing the right antifungal agent in ICU patients[J]. Adv Ther, 2019, 36(12): 3308-3320. DOI: 10.1007/s12325-019-01115-0.
[52]	KEANE S, GEOGHEGAN P, POVOA P, et al. Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis[J]. Expert Rev Anti Infect Ther, 2018, 16(11): 839-847. DOI: 10.1080/14787210.2018.1528872.
[53]	WANG T, YAN M, TANG D, et al. Using Child-Pugh class to optimize voriconazole dosage regimens and improve safety in patients with liver cirrhosis: Insights from a population pharmacokinetic model-based analysis[J]. Pharmacotherapy, 2021, 41(2): 172-183. DOI: 10.1002/phar.2474.
[54]	TANG D, YAN M, SONG BL, et al. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study[J]. Br J Clin Pharmacol, 2021, 87(4): 1890-1902. DOI: 10.1111/bcp.14578.
[55]	CHEN D, QIAN Z, SU H, et al. Invasive pulmonary aspergillosis in acute-on-chronic liver failure patients: Short-term outcomes and antifungal options[J]. Infect Dis Ther, 2021, 10(4): 2525-2538. DOI: 10.1007/s40121-021-00524-5.
[56]	GAO J, ZHANG Q, WU Y, et al. Improving survival of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis[J]. Sci Rep, 2018, 8(1): 876. DOI: 10.1038/s41598-018-19320-2.
[57]	SOLÍS-MUÑOZ P, LÓPEZ JC, BERNAL W, et al. Voriconazole hepatotoxicity in severe liver dysfunction[J]. J Infect, 2013, 66(1): 80-86. DOI: 10.1016/j.jinf.2012.09.011.
[58]	ULLMANN AJ, AGUADO JM, ARIKAN-AKDAGLI S, et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect, 2018, 24 Suppl 1: e1-e38. DOI: 10.1016/j.cmi.2018.01.002.
[59]	SLAVIN MA, THURSKY KA. Isavuconazole: A role for the newest broad-spectrum triazole[J]. Lancet, 2016, 387(10020): 726-728. DOI: 10.1016/S0140-6736(15)01218-0.
[60]	MU XD, QUE CL, HE B, et al. Caspofungin in salvage treatment of severe pneumocystis pneumonia: Case report and literature review[J]. Chin Med J (Engl), 2009, 122(8): 996-999. http://124.205.33.103:81/ch/reader/create_pdf.aspx?file_no=200941954310530&year_id=2009&quarter_id=8&falg=1
[61]	XIA XX, ZHU B, CHENG J, et al. Clinical study of AIDS complicated with Pneumocystis cafinii pneumonia[J]. Chin J Microecol, 2013, 25(4): 412-415. DOI: 10.13381/j.cnki.cjm.2013.04.027. 夏小学, 朱彪, 程进, 等. 艾滋病合并卡氏肺孢菌性肺炎临床探讨[J]. 中国微生态学杂志, 2013, 25(4): 412-415. DOI: 10.13381/j.cnki.cjm.2013.04.027.
[62]	ROMANI L, BISTONI F, GAZIANO R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll- like receptor signaling[J]. Blood, 2004, 103(11): 4232-4239. DOI: 10.1182/blood-2003-11-4036.
[63]	WU J, ZHOU L, LIU J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial[J]. Crit Care, 2013, 17(1): R8. DOI: 10.1186/cc11932.
[64]	SALGUEIRO LR, CAVALEIRO C, PINTO E, et al. Chemical composition and antifungal activity of the essential oil of Origanum virens on Candida species[J]. Planta Med, 2003, 69(9): 871-874. DOI: 10.1055/s-2003-43203.
[65]	PAPPAS PG, KAUFFMAN CA, ANDES DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 62(4): e1-e50. DOI: 10.1093/cid/civ933.
[66]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[67]	LIN F, WANG HF, SU HB, et al. Impacts of different fungous infections on severity and prognosis of patients with liver failure[J]. J Prac Hepatol, 2009, 12(1): 35-37. DOI: 10.3969/j.issn.1672-5069.2009.01.012. 林芳, 王慧芬, 苏海滨, 等. 不同真菌感染对肝衰竭患者病情及预后的影响[J]. 实用肝脏病杂志, 2009, 12(1): 35-37. DOI: 10.3969/j.issn.1672-5069.2009.01.012.
[68]	HWANG SY, YU SJ, LEE JH, et al. Spontaneous fungal peritonitis: A severe complication in patients with advanced liver cirrhosis[J]. Eur J Clin Microbiol Infect Dis, 2014, 33(2): 259-264. DOI: 10.1007/s10096-013-1953-2.
[69]	WANG Y, XU X, TONG JJ, et al. Analysis of prognosis and scoring systems in patients with liver failure combined with fungal infection[J]. Chin J Hepatol, 2020, 28(2): 168-171. DOI: 10.3760/cma.j.issn.1007-3418.2020.02.014. 王宇, 许祥, 童晶晶, 等. 肝衰竭合并真菌感染患者预后及评分系统分析[J]. 中华肝脏病杂志, 2020, 28(2): 168-171. DOI: 10.3760/cma.j.issn.1007-3418.2020.02.014.
[70]	ZENG XY, ZHOU W, ZHANG B. Effect of sodium bicarbonate brine gargle on prevention of oral fungal infections in patients undergoing radiotherapy[J]. Chin J Nosocomiol, 2015, 25(17): 4025-4027. DOI: 10.11816/cn.ni.2015-142323. 曾晓燕, 周维, 张波. 碳酸氢钠液含漱预防放疗患者口腔真菌感染的效果研究[J]. 中华医院感染学杂志, 2015, 25(17): 4025-4027. DOI: 10.11816/cn.ni.2015-142323.
[71]	HU L, WANG WY. Rinsing the mouth with sodium bicarbonate solution can reduce fungal infection in patients with liver failure[J]. Chin Hepatol, 2017, 22(10): 969-970. DOI: 10.3969/j.issn.1008-1704.2017.10.034. 胡玲, 汪文洋. 碳酸氢钠溶液漱口可减少肝衰竭患者真菌感染[J]. 肝脏, 2017, 22(10): 969-970. DOI: 10.3969/j.issn.1008-1704.2017.10.034.
[72]	ANDES DR, SAFDAR N, BADDLEY JW, et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)[J]. Transpl Infect Dis, 2016, 18(6): 921-931. DOI: 10.1111/tid.12613.
[73]	LUM L, LEE A, VU M, et al. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center[J]. Transpl Infect Dis, 2020, 22(6): e13361. DOI: 10.1111/tid.13361.
[74]	KANG WH, SONG GW, LEE SG, et al. A multicenter, randomized, open-label study to compare micafungin with fluconazole in the prophylaxis of invasive fungal infections in living-donor liver transplant recipients[J]. J Gastrointest Surg, 2020, 24(4): 832-840. DOI: 10.1007/s11605-019-04241-w.
[75]	ALBILLOS A, LARIO M, ÁLVAREZ-MON M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance[J]. J Hepatol, 2014, 61(6): 1385-1396. DOI: 10.1016/j.jhep.2014.08.010.
[76]	HUPRIKAR S. Revisiting antifungal prophylaxis in high-risk liver transplant recipients[J]. Am J Transplant, 2014, 14(12): 2683-2684. DOI: 10.1111/ajt.12989.
[77]	ASLAM S, ROTSTEIN C, AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13623. DOI: 10.1111/ctr.13623.
[78]	HUSAIN S, CAMARGO JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13544. DOI: 10.1111/ctr.13544.
[79]	GROLL AH, RIJNDERS B, WALSH TJ, et al. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B[J]. Clin Infect Dis, 2019, 68(Suppl 4): s260-s274. DOI: 10.1093/cid/ciz076.
[80]	SANSONE-PARSONS A, KRISHNA G, MARTINHO M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus[J]. Pharmacotherapy, 2007, 27(6): 825-834. DOI: 10.1592/phco.27.6.825.
[81]	SABLE CA, NGUYEN BY, CHODAKEWITZ JA, et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections[J]. Transpl Infect Dis, 2002, 4(1): 25-30. DOI: 10.1034/j.1399-3062.2002.01004.x.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (880) PDF downloads(279)

Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease

DOI: 10.3969/j.issn.1001-5256.2022.02.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease

DOI: 10.3969/j.issn.1001-5256.2022.02.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content